Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Heterologous Prime-Boost of AZD1222 and rAd26-S for COVID-19 Prevention
NCT04760730Phase 2Completed
- Sponsor
- R-Pharm
- Start
- Jul 2021
- Primary completion
- Mar 2022
- Modality
- Viral Vector Vaccines, Viral Vectors
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of ChAdOx1 nCoV-19 and rAd26 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by R-Pharm. Primary endpoint: Antibody seroconversion rate (>= 4 fold increase from baseline) against SARS-CoV-2 Spike protein at Day 57. Started Jul 2021; status: completed.
02
Drugs
ChAdOx1 nCoV-19rAd26
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04760730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04760730.